CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.
NFIB
OC
chemoresistance
circATL2
miR-506-3p
paclitaxel
Journal
Drug development research
ISSN: 1098-2299
Titre abrégé: Drug Dev Res
Pays: United States
ID NLM: 8204468
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
30
07
2021
received:
12
04
2021
accepted:
01
09
2021
pubmed:
21
9
2021
medline:
3
5
2022
entrez:
20
9
2021
Statut:
ppublish
Résumé
Circular RNAs (circRNAs) play vital regulatory roles in the development of ovarian cancer (OC). However, the functions of circRNA Atlastin GTPase 2 (circATL2) in paclitaxel (PTX) resistance of OC are still unclear. As a result, circATL2 was upregulated in PTX-resistant OC tissues and cells. CircATL2 knockdown reduced IC
Substances chimiques
MIRN506 microRNA, human
0
MicroRNAs
0
NFI Transcription Factors
0
NFIB protein, human
0
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
512-524Subventions
Organisme : Capilliposide from lysimachia capillipse affects epigenetics and restores taxol sensitivity in human ovarian cancer cells with acquire taxol resistance
ID : LGF18H160087
Organisme : Hangzhou Science and Technology Bureau, Social Autonomy Project
ID : 20170533B93
Organisme : Hangzhou Science and Technology Plan Guidance Project
ID : 20163501Y47
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Agarwal, R., & Kaye, S. B. (2003). Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nature Reviews Cancer, 3(7), 502-516.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424.
Chen, S. N., Chang, R., Lin, L. T., Chern, C. U., Tsai, H. W., Wen, Z. H., Tsui, K. H., Li, Y. H., & Li, C. J. (2019). MicroRNA in ovarian cancer: Biology, pathogenesis, and therapeutic opportunities. International Journal of Environmental Research and Public Health, 16(9), 1510.
Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annual Review of Medicine, 53, 615-627.
Guo, M., Li, S., Zhao, X., Yuan, Y., Zhang, B., & Guan, Y. (2020). Knockdown of circular RNA Hsa_circ_0000714 can regulate RAB17 by sponging miR-370-3p to reduce paclitaxel resistance of ovarian cancer through CDK6/RB pathway. Oncotargets and Therapy, 13, 13211-13224.
Haque, I., Kawsar, H. I., Motes, H., Sharma, M., Banerjee, S., Banerjee, S. K., … Huang, C. H. (2020). Downregulation of miR-506-3p facilitates EGFR-TKI resistance through induction of sonic hedgehog signaling in non-small-cell lung cancer cell lines. International Journal of Molecular Sciences, 21(23), 9307.
Hu, J., Wang, L., Chen, J., Gao, H., Zhao, W., Huang, Y., … Chen, Y. (2018). The circular RNA circ-ITCH suppresses ovarian carcinoma progression through targeting miR-145/RASA1 signaling. Biochemical and Biophysical Research Communications, 505(1), 222-228.
Kashiwagi, E., Izumi, H., Yasuniwa, Y., Baba, R., Doi, Y., Kidani, A., … Kohno, K. (2011). Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines. Cancer Science, 102(2), 382-386.
Li, J., Wu, H., Li, W., Yin, L., Guo, S., Xu, X., … Wang, H. (2016). Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-kappaB signaling. Oncogene, 35(42), 5501-5514.
Li, M., Cai, J., Han, X., & Ren, Y. (2020). Downregulation of circNRIP1 suppresses the paclitaxel resistance of ovarian cancer via regulating the miR-211-5p/HOXC8 Axis. Cancer Management and Research, 12, 9159-9171.
Lin, W., Ye, H., You, K., & Chen, L. (2020). Up-regulation of circ_LARP4 suppresses cell proliferation and migration in ovarian cancer by regulating miR-513b-5p/LARP4 axis. Cancer Cell International, 20, 5.
Liu, Q. Y., Jiang, X. X., Tian, H. N., Guo, H. L., Guo, H., & Guo, Y. (2020). Long non-coding RNA OIP5-AS1 plays an oncogenic role in ovarian cancer through targeting miR-324-3p/NFIB axis. European Review for Medical and Pharmacological Sciences, 24(13), 7266-7275.
Liu, R. Z., Vo, T. M., Jain, S., Choi, W. S., Garcia, E., Monckton, E. A., … Godbout, R. (2019a). NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer. The Journal of Pathology, 247(2), 186-198.
Liu, Z., Chen, J., Yuan, W., Ruan, H., Shu, Y., Ji, J., … Shu, X. (2019b). Nuclear factor I/B promotes colorectal cancer cell proliferation, epithelial-mesenchymal transition and 5-fluorouracil resistance. Cancer Science, 110(1), 86-98.
Llueca, A., Serra, A., Maiocchi, K., Delgado, K., Jativa, R., Gomez, L., & Escrig, J. (2019). Predictive model for major complications after extensive abdominal surgery in primary advanced ovarian cancer. International Journal of Women's Health, 11, 161-167.
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., … Rajewsky, N. (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature, 495(7441), 333-338.
Mihanfar, A., Fattahi, A., & Nejabati, H. R. (2019). MicroRNA-mediated drug resistance in ovarian cancer. Journal of Cellular Physiology, 234(4), 3180-3191.
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019). Chemotherapy resistance in advanced ovarian cancer patients. Biomarkers in Cancer, 11, 1179299X19860815.
Reed, N. S., & Symonds, R. P. (2018). Ovarian cancer. Clinical Oncology (Royal College of Radiologists), 30(8), 461-462.
Sassen, S., Miska, E. A., & Caldas, C. (2008). MicroRNA: Implications for cancer. Virchows Archiv, 452(1), 1-10.
Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7-30.
Sun, L., Fang, Y., Wang, X., Han, Y., Du, F., Li, C., … Wang, X. (2019). miR-302a inhibits metastasis and Cetuximab resistance in colorectal cancer by targeting NFIB and CD44. Theranostics, 9(26), 8409-8425.
Sun, Y., Wu, J., Dong, X., Zhang, J., Meng, C., & Liu, G. (2021). MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/beta-catenin in serous ovarian cancers. Translational Oncology, 14(2), 100987.
Wei, W., & Birrer, M. J. (2015). Spleen tyrosine kinase confers paclitaxel resistance in ovarian cancer. Cancer Cell, 28(1), 7-9.
Xia, B., Zhao, Z., Wu, Y., Wang, Y., Zhao, Y., & Wang, J. (2020). Circular RNA circTNPO3 regulates paclitaxel resistance of ovarian cancer cells by miR-1299/NEK2 signaling pathway. Molecular Therapy Nucleic Acids, 21, 780-791.
Xing, S., Qu, Y., Li, C., Huang, A., Tong, S., Wu, C., & Fan, K. (2019). Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT. Journal of Cellular Physiology, 234(12), 22657-22665.
Xu, T., Wang, M., Jiang, L., Ma, L., Wan, L., Chen, Q., … Wang, Z. (2020). CircRNAs in anticancer drug resistance: Recent advances and future potential. Molecular Cancer, 19(1), 127.
Yang, S., Li, Z., & Luo, R. (2020). miR-34c targets MET to improve the anti-tumor effect of Cisplatin on ovarian cancer. Oncotargets and Therapy, 13, 2887-2897.
Zhang, S., Cheng, J., Quan, C., Wen, H., Feng, Z., Hu, Q., … Wu, X. (2020). circCELSR1 (hsa_circ_0063809) contributes to paclitaxel resistance of ovarian cancer cells by regulating FOXR2 expression via miR-1252. Molecular Therapy Nucleic Acids, 19, 718-730.
Zhang, X. L., Sun, B. L., Tian, S. X., Li, L., Zhao, Y. C., & Shi, P. P. (2019). MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1. European Review for Medical and Pharmacological Sciences, 23(9), 3635-3644.
Zhao, Z., Ji, M., Wang, Q., He, N., & Li, Y. (2019). Circular RNA Cdr1as Upregulates SCAI to suppress Cisplatin resistance in ovarian cancer via miR-1270 suppression. Molecular Therapy Nucleic Acids, 18, 24-33.
Zheng, Y., Li, Z., Yang, S., Wang, Y., & Luan, Z. (2020). CircEXOC6B suppresses the proliferation and motility and sensitizes ovarian cancer cells to paclitaxel through miR-376c-3p/FOXO3 Axis. Cancer Biotherapy & Radiopharmaceuticals. Online Ahead of Print.
Zhou, H., Lin, C., Zhang, Y., Zhang, X., Zhang, C., Zhang, P., … Ren, Z. (2017). miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression. Cell Proliferation, 50(3), e12341.
Zuo, Y., Zheng, W., Tang, Q., Liu, J., Wang, S., & Xin, C. (2021). miR5763p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PDL1 and cyclin D1. Molecular Medicine Reports, 23(1), 81.